Rate of phenytoin accumulation in man: A simulation study
Tóm tắt
Computer simulations were performed using a one-compartment open model with either first-order or zero-order input and either Michaelis-Menten or Michaelis-Menten and first-order elimination. Twelve theoretical cases constructed from various combinations of typical and atypical values for phenytoin pharmacokinetic parameters, V
max
and K
m
, were examined. In many cases, at least 90% of the eventual steady-state serum level would be achieved within 4 weeks when phenytoin was administered at an appropriate rate. In the case of a low-to-average Vmax value and an average-to-high Km value, an initial maintenance dose of 3–4 mg phenytoin sodium/kg/day would, within a few days, result in serum phenytoin levels above the usual therapeutic range. On the other hand, if V
max
and K
m
values were both low (3.8 mg/kg/day and 1.45 mg/liter, respectively), a very slow rate of accumulation would ensue. Thirty days after the start of 4 mg phenytoin sodium/kg/day, a serum level of about 16 μg/ml would likely occur. The magnitude of continued accumulation beyond this level would be significantly influenced by the rate of renal elimination of unchanged phenytoin. It is recommended that, after initiation or adjustment of phenytoin therapy, serum phenytoin levels be monitored weekly for 3–4 weeks, then monthly for 2 additional months. Long-term follow-up should include serum phenytoin levels every 3– 6 months or as clinically indicated. Appreciation of the characteristics of phenytoin accumulation in relation to rate of administration and individual pharmacokinetic parameters is important for accurate interpretation of serum phenytoin levels and rational adjustment of dosage regimens.
Từ khóa
Tài liệu tham khảo
K. Arnold and N. Gerber. The rate of decline of diphenylhydantoin in human plasma.Clin. Pharmacol. Ther. 11:121–134 (1970).
A. J. Atkinson and J. M. Shaw. Pharmacokinetic study of a patient with diphenylhydantoin toxicity.Clin. Pharmacol. Ther. 14:521–528 (1973).
M. J. Eadie, J. H. Tyrer, F. Bochner, and W. D. Hooper. The elimination of phenytoin in man.Clin Exp. Pharmacol. Physiol. 3:217–224 (1976).
L. K. Garrettson and W. J. Jusko. Diphenylhydantoin elimination kinetics in overdosed children.Clin. Pharmacol. Ther. 17:481–491 (1975).
N. Gerber and J. G. Wagner. Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.Res. Commun. Chem. Pathol. Pharmacol. 3:455–466 (1972).
A. J. Glazko, T. Chang, J. Baukema, W. A. Dilla, J. R. Gaulet, and R. A. Buchanan. Metabolic disposition of diphenylhydantoin in normal subjects following intravenous administration.Clin. Pharmacol. Ther. 10:498–504 (1969).
J. M. Letteri, H. Mellk, S. Louis, H. Kutt, P. Durante, and A. Glazko. Diphenylhydantoin metabolism in uremia.New Engl. J. Med. 285:648–652 (1971).
A. Richens. A study of the pharmacokinetics of phenytoin (Diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments.Epilepsia 16:627–646 (1975).
C. Hoppel, M. Garle, A. Rane, and F. Sjoqvist. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.Clin. Pharmacol. Ther. 21:294–300 (1977).
N. Gerber, R. Lynn, and J. Oates. Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation.Ann. Intern. Med. 77:765–771 (1972).
G. E. Mawer, P. W. Mullen, M. Rodgers, A. J. Robins, and S. B. Lucas. Phenytoin dose adjustment in epileptic patients.Br. J. Clin. Pharmacol. 1:163–168 (1974).
T. M. Ludden, J. P. Allen, W. A. Valutsky, A. V. Vicuna, J. M. Nappi, S. F. Hoffman, J. E. Wallace, D. Lalka, and J. L. McNay. Individualization of phenytoin dosage regimens.Clin. Pharmacol. Ther. 21:287–293 (1977).
W. J. Jusko, J. R. Koup, and G. Alvan. Nonlinear assessment of phenytoin bioavailability.J. Pharmacokin. Biopharm. 4:327–336 (1976).
W. J. Jusko. Bioavailability and disposition kinetics of phenytoin in man. In P. Kellaway and I. Petersen (eds.),Quantitative Analytical Studies in Epilepsy, Raven Press, New York, 1976, pp. 115–136.
E. Martin, T. N. Tozer, L. B. Sheiner, and S. Riegelman. The clinical pharmacokinetics of phenytoin.J. Pharmacokin. Biopharm. 5:579–596 (1977).
A. E. Staubus, S. Riegelman, and J. A. Nelson. Theoretical considerations of capacitylimited kinetics. Presented to the Basic Pharmaceutics Section at the Meeting of the APhA Academy of Pharmaceutical Sciences, Chicago, August 3–8, 1974.
J. G. Wagner. Time to reach steady state and prediction of steady state concentrations for drugs obeying Michaelis-Menten elimination kinetics.J. Pharmacokin. Biopharm. 6:209–225 (1978).
R. J. Sawchuk, J. C. Cloyd, I. E. Leppik, S. M. Pepin, and R. J. Gumnit. Steady state analysis of phenytoin kinetics applied to dose adjustments in epileptic patients. Presented at the Basic Pharmaceutics Section at the Meeting of the APhA Academy of Pharmaceutical Sciences, Phoenix, November 13–17, 1977.
P. W. Mullen. Optimal phenytoin therapy: A new technique for individualizing dosage.Clin. Pharmacol. Ther. 23:228–232 (1978).
F. Bochner, W. D. Hooper, J. M. Sutherland, M. J. Eadie, and J. H. Tyrer. The renal handling of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin.Clin. Pharmacol. Ther. 14:791–796 (1973).
M. Dovell and P. Jarratt. A modifiedregula falsi method for computing the root of an equation.BIT 11:168–174 (1971).
P. J. Pentikainen, P. J. Neuvonen, and S. M. Elfving. Bioavailability of four brands of phenytoin tablets.Eur. J. Clin. Pharmacol. 9:213–218 (1975).
M. J. Stewart, B. R. Ballinger, E. J. Devlin, A. Y. Miller, and A. C. Ramsey. Bioavailability of phenytoin: A comparison of two preparations.Eur. J. Clin. Pharmacol. 9:209–212 (1975).
L. N. Sansom, W. J. O'Reilly, C. W. Wiseman, L. M. Stern, and J. Derham. Plasma phenytoin levels produced by various phenytoin preparations.Med. J. Aust. 2:593–595 (1975).
A. P. Melikian, A. B. Straughn, G. W. A. Slywka, R. P. Whyatt, and M. C. Meyer. Bioavailability of 11 phenytoin products.J. Pharmacokin. Biopharm. 5:133–146 (1977).
D. G. Lambie, R. H. Johnson, R. N. Nanda, and R. A. Shakir. Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy.Lancet 2:386–389 (1976).
G. J. Ayers, J. H. Goudie, and D. Burnett. Serum-phenytoin and body weight.Lancet 1:809–810 (1976).
R. J. Porter and R. B. Layzer. Plasma albumin concentration and diphenylhydantoin binding in man.Arch. Neurol. 32:298–303 (1975).